Thursday, August 16, 2012

Honeywell 2Q2012


     On July 18, 2012 Honeywell reported earnings of $1.14 a share, beating the street estimate of $1.12 set out by the 20 analysts covering the company. The company’s second quarter profit rose 11% as the company’s revenues were $9.44 billion, an increase of 4%, just under the projection of $9.56 billion. The company then proceeded to adjust expected revenues FY2012 by decreasing the range of 37.8 billion-38.4 billion from $38 billion- 38.6 billion. Despite this decrease in projected earnings, we see the company raising its FY2012 outlook to $4.40-$4.55. This represents a trend that we have been seeing across the street this earnings season. Many companies have been able to beat projected EPS, while underperforming in regards to revenue. This trend suggests a move towards greater efficiency and could mean the loss of jobs across America. CEO Dave Cote had this to say of the changes in projections, “Given the increasingly uncertain global economic environment, we’ll remain flexible, but also continue to invest in sustainable growth through seed planting in new products and technologies, geographic expansion and our key initiatives.”

     A global leader in the making of aerospace, building-control and safety products, Honeywell has received a total of 4 Strong Buys, 10 Buys, and 6 Holds according to CNBC. They have benefited from a steady increase in demand across all major segments. Their extensive work with Boeing generated an increase in their aerospace unit of 8%. We saw Honeywell sign a deal with satellite-operator Immarsat to manufacture equipment for airborne broadband connections, which will last 20 years, and could create up to $2.8 billion in revenues. 

Friday, August 10, 2012

BSX F2Q12 Earnings 6/27/12 - (Ryan Kennedy)

     Boston Scientific (BSX) released second quarter earnings on July 26th for the period ended June 30th. The company reported sales of $1.82bn and adjusted EPS of $0.17. Revenues fell 4% from Q2 2011 on a constant currency basis, driven by eroding sales in the Interventional Cardiology and Cardiac Rhythm Management segments, but somewhat tempered by growth in the Neuromodulation, Endoscopy, and Peripheral Intervention business units. Despite adjusted EPS at the high-end of management’s guidance, the stock traded down throughout the day on weakening sales in the business’ two core segments.
   
     Excluding divested businesses, the firm reported revenues of $1.8bn compared to $1.9bn a year ago. Revenues from Interventional Cardiology, the firm’s stent business, saw the largest drop of 13%, from $652mm to $549mm. The Cardiac Rhythm Management unit, the firm’s ICD and pacemaker unit and also the firm’s second largest division, also fell 8%, from $544mm to $488mm. The CRM division has slowed on decreased procedural volumes, driven by a study in the Journal of the American Medical Association and subsequent Department of Justice investigations into non-evidence based ICD implants. Despite disappointing performance from the business’ two largest segments, BSX continues to have positive growth in its smaller units, which are continually becoming more significant parts of the business. The Neuromodulation unit, which produces implantable electronic devices used to control chronic pain, continued its strong performance, growing from $84mm to $91mm, or 10% on a constant currency basis. The Endoscopy and Peripheral Interventions units also saw moderate growth of 7%, from $298mm to $311mm and $189mm to $196mm, respectively.

     BSX continues to make strides in profitability. The firm increased gross margin by 322 bps, from 65% to 68%, as the firm continues its transition from the lower-margin Promus stent to the higher-margin Promus Element. After removing one-time items, EBITDA margin increased 22 bps despite increases in SG&A and R&D as percentages of sales, primarily driven by the increase in gross margin. On an absolute basis, SG&A grew by $6mm, while R&D fell by $10mm and EBITDA dropped $23mm. Boston Scientific continues to pay down debt and reduce interest expense, which has historically weighed on earnings since the firm took on $6.5bn in debt to acquire Guidant in 2006. The firm reported interest expense of $64mm compared to $73mm a year ago. After removing a $3.4bn non-cash goodwill impairment charge associated with the EMEA unit, BSX reported net income of $242mm or $0.17 a share. On a GAAP basis, the company reported a net loss of $3.4bn or $2.39 per share.
   
     Going forward, we are bullish on Boston Scientific. The company has been trading based on revenue growth in the CRM and Interventional Cardiology units, but there is more than meets the eye. Despite contractions in the two main business segments, the company continues to have significant growth in the Neuromodulation and Endoscopy units, which are now becoming sizable portions of the company, and should begin to have a larger effect on the stock price. The company continues to make strides in profitability and unload the debt levels that have suppressed the stock over the past six years. Overall the company is stronger and more financially sound, but needs a catalyst in the IC or CRM units to reawaken the stock and allow investors to focus on improved financials. The PROMUS Element, which has been brought to market but is still in its infancy, may be the catalyst needed to bolster Interventional Cardiology revenues. Aside from the Element, there are very positive new developments in the Cardiac Rhythm Management unit, with the $150mm acquisition of Cameron Health and its subcutaneous S-ICD device. The S-ICD device has the potential to be a $750mm market, and BSX is the only company that has such a device. Considering the firm’s improved health, its strong operating cash flow generation of $407mm, and catalysts in the Element and S-ICD, we are bullish on BSX and believe 2013 will be particularly strong for the firm.

Thursday, August 9, 2012

VZ Sell Thesis


Verizon has outperformed and came just shy of our $46 price target. We decided to cut the position in half for the following reasons:

-Verizon has outperformed since late April/May, largely due to a defensive shift in investor sentiment. The low interest rate environment has pushed money into “safe-haven stocks” like Verizon, which now has a 4.5% yield (this was much higher before the run up). 
-We still believe in the company’s thesis and reiterate its $46 PT, but would like to take some profits at this time because the upside is limited & as a precaution in case investors shift more into risky assets and out of high yield stocks in the telecom industry.
-In addition to a sector rotation thesis, there are some fundamental negatives that could cause the stock to pause: 
   -Customers viewing family share pricing as expensive could limit sales. Forcing them to get rid of unlimited data unless you buy phones outright creates customer resentment as well. Prepaid carriers are starting to make a push, with Virgin Mobile leading the way with the iPhone and other high-end smartphones 
   -Deceleration in FiOS volumes in video & data, absence of a new labor agreement could be a negative, & weakness in wholesales.


-Ryan Ranado & Joe Esposito

Qualcomm Earnings release

Qualcomm released earnings results on July 19th, posting EPS of 86 cents, which was in-line with expectations. They also posted a 28% increase year over year in revenues at $4.63 billion. Company guidance for the fourth quarter EPS of 78-84 cents came in slightly below the consensus expectations of 89 cents, due to lower projections in smartphone sales. CEO Dr. Paul Jacobs states that their estimates in 3G/4G device shipments have changed as they expect demand “to be more back-end loaded as devices are launched for the holiday season.” They saw margins drop slightly over the quarter, gross margins coming in at 64.4% compared with 64.7% last year, and operating margins at 30.0% compared with 31.0% last year. Sales of their 3G and 3G/4G chipsets have been driving their revenue growth as countries all over the world continue to adopt mobile platforms. They shipped 141 million MSM chip units, up 18% from last year. The approximate selling price of each 3G/4G unit rose from $226 to $232. With the gradual adaptation of 4G LTE handsets in developed markets such as the U.S. and Japan, as well as the overwhelming demand of smartphones in emerging markets Qualcomm is in position to benefit from these macro trends. One factor that shouldn’t be overlooked is the decline in smartphone pricing, which could negatively affect Qualcomm’s margins.


-Ryan Ranado

Verizon Earnings Release

Verizon announced earnings results on July 16th, they reported EPS of 64 cents, a 12.3% increase year over year, which met analysts’ expectations. They posted record highs in operating income margin at 30.8% and EBITDA margin of 49%. The wireless segment increased revenues 7.3% year over year, added 1.2 million retail customers; 888,000 of which were postpaid customers. The wireline segment saw increases of 2.5 percent in revenues, with 65% of revenues generated by Verizon FiOS. Verizon had a 3 percent increase in smartphone users, bringing in 50% of their postpaid revenues from smartphone customers. Verizon released its Share Everything plan on June 28th, offering customers unlimited calling, texting, and shareable data, increasing the amount of devices allowed from 5 to 10. The new plans offer cheaper pricing for customers with more devices, however slightly higher pricing for feature phone customers. They also had the release of the Samsung Galaxy S III which has been a top selling smartphone thus far, which will benefit Verizon’s margins if more customers choose to use that over the iPhone. Looking forward Verizon remains the leading competitor in the 4G LTE market, they have enabled customers to add multiple data devices such as tablets and broadband cards for very affordable rates, and their FiOS services continue to grow and penetrate into new markets. These key points will allow them to grow their business and continue to remain the market leader in mobile telecommunications.

-Ryan Ranado

Tuesday, August 7, 2012

LIFE 2QF2012 Earnings


Life Technologies finished the first half of the year in line with their expectations, and revenue for the quarter even came in a little bit higher than they expected at $950 million. Revenue growth came in at 5%, if the expected headwinds from a decline in their SOLID platform are excluded. Net income rose from 52 cents per share to 67 cents per share year over year and EPS missed analysts’ estimates by $0.01 at $0.96 cents per share. During the quarter, they repurchased $150 million worth in shares. Emerging markets such as Asia continued to drive growth, while their push into the medical diagnostics markets in Hospitals and clinics has also helped.
Life Technologies recently opened a plant in Singapore. This is a move that signifies their increased penetration in Asian markets. Life recently announced plans to accelerate the development of their Ion Torrent sequencer after meeting internal goals and is seeing a strong demand for it. On July 16, they acquired Navigenics, a company that can provide clinical diagnostic testing laboratories for life to test kits for its upcoming sequencer, showing that it will keep trying to push the new machine into the clinical and diagnostic market.
Looking forward, Life Technologies trimmed their year EPS by $0.05 to $4.00 on the high end, while remaining stable on the low end of $3.90. They also expect their total revenue growth to be more towards the low end of 2 - 4%. Life technologies has revised their projections because of a bleak macro situation in Europe and recent acquisitions to drive their Medical Sciences segment. Additionally, while there hasn’t been any NIH budget cuts recently, they continue to monitor the sequestration and budget news coming from congress, as a cut could affect spending in their academic market.
LIFE continues to be extremely bullish on their upcoming Proton sequencer, exceeding company expectations in both performance and demand from customers. They see emerging markets in Asia and the medical and diagnostics market in the US as primary drivers of growth, especially in the fourth quarter of 2012. They have taken into account macro conditions in Europe and continue to monitor budgetary policies in the US. We remain positive on the stock, but continue to monitor news from competitors’ pipelines, Europe, and budgetary policies in the US. 

-Jorge Perez

Monday, August 6, 2012

MetLife Second Quarter Earnings 2012


MetLife reported earnings on Wednesday, August 1st with operating earnings of $1.33 beating analysts’ mean estimate by 9 cents and our own estimates by 8 cents per share. Variable annuity sales were greatly reduced down 34% for the quarter and 6% year over year as MetLife works to balance its growth and risk. Operating profit in the firm’s Asia region was up 61% year over year as life insurance sales in Japan rose in comparison to the tsunami burdened Q2 of last year. Shares closed up 4.2% on Thursday and as of this writing are up 10.5% outpacing the SP500 by 8.8% over the same period.

                Management still projects an ROE of 12% to 14% by 2016 despite the low interest rate environment. In the event that 10-year Treasuries remain at 1.4% they feel they will still be able to hit the low end of that range. MetLife has thus far been very successful with its hedging program with a 1.4 billion derivatives gain tied to low interest rates this quarter and has multiple products that it can adjust interest rates on to adapt to market conditions.

                On the regulatory front MetLife’s application to complete the sale of MetLife bank to GE Capital is under review by the FDIC and management did not speculate on a timeframe for any action. The possibility of MetLife being classified as a nonbank SIFI still looms over the stock but it is unclear what the impact may be as the rules are not yet clear.

                Our outlook is positive as MetLife continues to focus on sound pricing and underwriting with appropriate levels of risk management.